Search

Cogent Biosciences Inc

Fechado

40.26 1.74

Visão Geral

Variação de preço das ações

24h

Atual

Mín

38.99

Máximo

39.8

Indicadores-chave

By Trading Economics

Rendimento

5.1M

-97M

EPS

-0.53

Funcionários

258

EBITDA

14M

-95M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+31.87% upside

Dividendos

By Acuity

Próximos Ganhos

4 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

271M

6.5B

Abertura anterior

38.52

Fecho anterior

40.26

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de jul. de 2026, 23:56 UTC

Cryptocurrency values rise as global equity markets approach $166 trillion amid mixed sentiment and geopolitical uncertainties.

26 de jul. de 2026, 23:56 UTC

"Ethereum and Bitcoin rise amid mixed market sentiment as Japan shifts to expansionary fiscal policy and key economic data looms."

26 de jul. de 2026, 23:56 UTC

"Ethereum Rises 4.2% Amidst Strong Global Equity Markets and Upcoming Key Economic Data Releases."

26 de jul. de 2026, 23:56 UTC

Cryptocurrency gains amid cautious investor sentiment in global equities as markets brace for key economic data and Fed interest rate decision.

26 de jul. de 2026, 23:52 UTC

Australia's RBA Trimmed Mean CPI Release on July 29, 2026, Expected to Impact Monetary Policy Amid Rising Trade Tensions and Cost-of-Living Concerns.

26 de jul. de 2026, 23:52 UTC

Australia's Inflation Rate YoY Data Set for Release on July 29, 2026, with Forecasted Increase to 4.1%, Impacting Monetary Policy and Market Sentiment.

26 de jul. de 2026, 23:51 UTC

Correlated Moves

EUR/CAD shows a slight increase in after-hours trading, reflecting volatility and aligning with a similar uptick in EUR/USD amid comparable macroeconomic factors.

26 de jul. de 2026, 23:51 UTC

EUR/SEK shows notable weakness in after-hours trading, declining since Friday's close and reaching a session low amid unusual downward pressure.

26 de jul. de 2026, 23:51 UTC

Macro News
Correlated Moves

Bitcoin prices have risen to $65,392, reflecting optimism amid speculation of reaching $180,000. Trade tensions could impact global markets, including cryptocurrencies.

26 de jul. de 2026, 23:41 UTC

GBP/CAD advances slightly in after-hours trading, positioned near the lower end of its one-month range. No specific news was identified for the move.

26 de jul. de 2026, 23:41 UTC

Upcoming U.S. Employment Cost Index report on July 31 to reveal key wage growth data amid rising inflation and consumer concerns over grocery prices.

26 de jul. de 2026, 23:41 UTC

Employment Cost Index for Q2 2026 set to rise by 0.8%, signaling potential implications for inflation and Federal Reserve interest rate decisions.

26 de jul. de 2026, 23:41 UTC

U.S. Employment Cost Index Benefits Data Set for Release on July 31, 2026, Amid Global Labor Market Dynamics and Inflation Concerns.

26 de jul. de 2026, 23:41 UTC

Canada's preliminary monthly GDP report on July 31, 2026, is anticipated to reveal growth amid mixed economic signals and external risks.

26 de jul. de 2026, 23:23 UTC

Upcoming PCE Price Index Release on July 30, 2026, Expected to Reflect Consumer Inflation Amid Rising Grocery Prices and Economic Pressures.

26 de jul. de 2026, 23:23 UTC

U.S. PCE Price Index Expected to Rise 0.4% in June Amid Ongoing Inflation Concerns and Consumer Behavior Shifts

26 de jul. de 2026, 23:23 UTC

U.S. Personal Spending MoM Data Release on July 30, 2026 Expected to Show 0.4% Growth Amid Rising Grocery Prices and Changing Consumer Habits.

26 de jul. de 2026, 23:23 UTC

Core PCE Price Index MoM for June 2026 set to release on July 30, with a modest forecasted increase of 0.1%, as markets remain cautiously optimistic amid mixed equity performance and Fed policy discussions.

26 de jul. de 2026, 23:23 UTC

US Personal Income MoM Data Release on July 30, 2026 Expected to Show Modest 0.3% Increase Amid Mixed Economic Signals

26 de jul. de 2026, 23:23 UTC

U.S. GDP Price Index Forecasted to Rise 3.7% Amid Inflation Concerns Ahead of July Release

26 de jul. de 2026, 23:23 UTC

U.S. Q2 2026 GDP Growth Rate Release Forecasts 2.3% Amid Cautious Market Sentiment and Rising Consumer Prices

26 de jul. de 2026, 23:23 UTC

South Korea's July export growth expected to remain strong at 70.9% YoY amid market volatility and global uncertainties, with a report due August 1, 2026.

26 de jul. de 2026, 23:13 UTC

South Africa's upcoming balance of trade data on July 31, 2026, is crucial as it follows a surprising May deficit amid rising imports and declining exports.

26 de jul. de 2026, 23:13 UTC

S&P/Case-Shiller Home Price Index Expected to Show Modest 0.8% YoY Growth Amid Cooling U.S. Housing Market and High Inflation Concerns

26 de jul. de 2026, 23:11 UTC

Correlated Moves
News

Ethereum is rising during Sunday’s trading session, gaining alongside Bitcoin amid strong market activity and global developments influencing investor sentiment.

26 de jul. de 2026, 23:11 UTC

Correlated Moves
News

Ethereum is advancing during Sunday’s session, supported by Bitcoin's upward movement. The asset is trading well above recent averages amid strong market activity.

26 de jul. de 2026, 23:02 UTC

After-market trading for SGD/CHF shows an upward trend, gaining since Friday's close. It is currently 1.09% above its 20-day moving average.

26 de jul. de 2026, 23:01 UTC

GBP/CHF moved higher during after-market hours, reflecting strong momentum near the upper end of its one-month range. No specific news was identified.

26 de jul. de 2026, 23:01 UTC

Correlated Moves

GBP/HKD is trading higher in after-market hours, reflecting a cumulative return that peaked at 0.30%. The pair shows unusual strength amid recent EUR/USD gains.

26 de jul. de 2026, 23:01 UTC

Brazil's Unemployment Rate Release on July 30 Expected to Show Continued Improvement Amid Economic Optimism and External Challenges.

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

31.87% parte superior

Previsão para 12 meses

Média 52.43 USD  31.87%

Máximo 60 USD

Mínimo 45 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
help-icon Live chat